口服水飞蓟宾胶囊联合吡柔比星膀胱灌注对非肌层浸润性膀胱癌患者术后复发的影响  

Effect of oral silibinin capsules combined with pirarubicin bladder infusion on the recurrence of bladder cancer in patients with non-muscle invasive bladder cancer

作　　者：段万里[1] 管振锋 赵华才[1] 邓骞 程永毅[1] 孙羿[1] DUAN Wanli;GUAN Zhenfeng;ZHAO Huacai;DENG Qian;CHENG Yongyi;SUN Yi(Department of Urology,Shaanxi Provincial People's Hospital,Shaanxi Xi'an 710068,China)

机构地区：[1]陕西省人民医院泌尿外科,陕西西安710068

出　　处：《现代肿瘤医学》2021年第10期1728-1732,共5页Journal of Modern Oncology

基　　金：陕西省重点项目-社会发展领域(编号:2017ZDXM-SF-050);陕西省一般项目-青年项目(编号:2020JQ-945)。

摘　　要：目的:观察口服水飞蓟宾胶囊联合吡柔比星膀胱灌注对非肌层浸润性膀胱癌患者术后复发的影响。方法:将非肌层浸润性膀胱癌患者124例患者随机分为对照组62例和观察组62例,对照组给予吡柔比星膀胱灌注,观察组给予口服水飞蓟宾胶囊联合吡柔比星膀胱灌注。单因素分析性别、年龄、血尿、吸烟、肿瘤数目、肿瘤大小、肿瘤病理分级、肿瘤分期、水飞蓟宾联合吡柔比星对膀胱肿瘤复发的影响。将单因素分析可能影响肿瘤复发的因素纳入多因素Cox回归分析独立影响肿瘤复发的因素。结果:单因素分析结果提示肿瘤数目、肿瘤大小、肿瘤病理分级、肿瘤分期、水飞蓟宾联合吡柔比星可能是影响膀胱肿瘤复发的因素(P<0.05);多因素Cox回归分析显示肿瘤多发、T 1是非肌层浸润性膀胱癌的独立危险因素(P<0.05),水飞蓟宾联合吡柔比星是非肌层浸润性膀胱癌的独立保护因素(P<0.01)。结论:口服水飞蓟宾胶囊联合吡柔比星膀胱灌注对非肌层浸润性膀胱癌TUR-BT术后复发的预防效果较好,可减少患者术后早期复发率,且不增加不良反应,较为安全,值得临床推广应用。Objective:To observe the effect of oral silibinin capsules combined with pirarubicin bladder infusion on the recurrence of bladder cancer in patients with non-muscle invasive bladder cancer.Methods:124 patients with non-muscle invasive bladder cancer were randomly divided into a control group of 62 cases and an observation group of 62 cases.The control group was given pirarubicin bladder infusion,and the observation group was given oral silibinin capsules combined with pirarubicin bladder infusion.Univariate analysis detected the effects of gender,age,hematuria,smoking,tumor number,tumor size,tumor pathological grade,tumor stage,silibinin combined with pirarubicin on bladder tumor recurrence.Factors that may affect tumor recurrence in univariate analysis were included in multivariate Cox regression analysis to determine independent factors that affect tumor recurrence.Results:The results of univariate analysis suggested that the number of tumors,tumor size,tumor pathological grade,tumor stage,silibinin combined with pirarubicin may be the factors affecting the recurrence of bladder tumors(P<0.05).Multivariate Cox regression analysis showed multiple tumors and T 1 were independent risk factors for non-muscle invasive bladder cancer(P<0.05),and silibinin combined with pirarubicin was an independent protective factor for non-muscle invasive bladder cancer(P<0.01).Conclusion:Oral silibinin capsules combined with pirarubicin bladder infusion has a better preventive effect on the recurrence of non-muscle invasive bladder cancer after TUR-BT,which can reduce the early recurrence rate of patients after surgery without increasing adverse reactions.It is relatively safe and worthy of clinical application.

关 键 词：非肌层浸润性膀胱癌 复发 水飞蓟宾 吡柔比星 影响因素 

分 类 号：R737.14[医药卫生—肿瘤]